Michael Zinda - Mar 28, 2024 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role
EVP, CHIEF SCIENTIFIC OFFICER
Signature
/s/ Steve Forte, Attorney-in-Fact
Stock symbol
RPTX
Transactions as of
Mar 28, 2024
Transactions value $
-$3,999
Form type
4
Date filed
4/1/2024, 09:28 PM
Previous filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Shares Sale -$2.09K -450 -0.62% $4.64 72.3K Mar 28, 2024 Direct F1, F2
transaction RPTX Common Shares Sale -$1.91K -410 -0.57% $4.66 71.9K Apr 1, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 24,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 8,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.53 to $4.76 inclusive.